201 related articles for article (PubMed ID: 30568562)
1. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
[TBL] [Abstract][Full Text] [Related]
2. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
Al-Keilani MS; Almomani BA
Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
[TBL] [Abstract][Full Text] [Related]
3. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
4. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
[No Abstract] [Full Text] [Related]
5. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
6. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
Mardan J; Hussain MA; Allan M; Grech LB
J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
[No Abstract] [Full Text] [Related]
7. Treatment satisfaction with disease-modifying therapy is the only predictor of Adherence among multiple sclerosis patients from Upper Egypt.
Khedr EM; Mahmoud DM; Hussein HB; Malky IEL; Mostafa SS; Gamea A
Sci Rep; 2024 Mar; 14(1):7027. PubMed ID: 38528018
[TBL] [Abstract][Full Text] [Related]
8. Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide.
Štrosová D; Tužil J; Turková BV; Pilnáčková BF; de Souza LL; Doležalová H; Rašková M; Dufek M; Doležal T
Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297360
[No Abstract] [Full Text] [Related]
9. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Burkhard A; Toliver J; Rascati K
J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
[No Abstract] [Full Text] [Related]
10. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
13. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
Burks J; Marshall TS; Ye X
Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
[TBL] [Abstract][Full Text] [Related]
14. Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis.
Neter E; Glass-Marmor L; Wolkowitz A; Lavi I; Miller A
BMC Neurol; 2021 Mar; 21(1):136. PubMed ID: 33761887
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
[TBL] [Abstract][Full Text] [Related]
16. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
Higuera L; Carlin CS; Anderson S
J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
[TBL] [Abstract][Full Text] [Related]
17. Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis.
Zanga G; Drzewiscki E; Tagliani P; Smietniansky M; Esnaola Y Rojas MM; Caruso D
Ther Adv Neurol Disord; 2021; 14():17562864211031099. PubMed ID: 34630632
[TBL] [Abstract][Full Text] [Related]
18. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
[TBL] [Abstract][Full Text] [Related]
19. Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
Fernández O; Duran E; Ayuso T; Hernández L; Bonaventura I; Forner M;
PLoS One; 2017; 12(10):e0185766. PubMed ID: 29049356
[TBL] [Abstract][Full Text] [Related]
20. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
